Vehicles for genetic vaccines against human immunodeficiency virus: induction of T cell-mediated immune responses.

Vehicles for genetic vaccines against human immunodeficiency virus: induction of T cell-mediated immune responses.

Success of a candidate vaccine against human immunodeficiency virus (HIV) depends on the type, site, strength, longevity and specificity of the immune responses it induces. The specificity of a vaccine is determined by the HIV-derived immunogens it employs in its formulation. Central to the other fe...

Bibliografski detalji
Glavni autor:	Hanke, T
Format:	Journal article
Jezik:	English
Izdano:	2001

Slični predmeti

DNA vaccines against human immunodeficiency virus type 1.
od: Estcourt, M, i dr.
Izdano: (2004)

Simian immunodeficiency virus-specific cytotoxic T lymphocytes and protection against challenge in rhesus macaques immunized with a live attenuated simian immunodeficiency virus vaccine.
od: Nixon, D, i dr.
Izdano: (2000)

Clinical experience with plasmid DNA- and modified vaccinia virus Ankara-vectored human immunodeficiency virus type 1 clade A vaccine focusing on T-cell induction.
od: Hanke, T, i dr.
Izdano: (2007)

Booster vaccination against SARS-CoV-2 induces potent immune responses in people with human immunodeficiency virus
od: Fidler, S, i dr.
Izdano: (2022)

Induction of human immunodeficiency virus type 1-specific T cells by a bluetongue virus tubule-vectored vaccine prime-recombinant modified virus Ankara boost regimen.
od: Larke, N, i dr.
Izdano: (2005)

Enhanced immunogenicity using an alphavirus replicon DNA vaccine against human immunodeficiency virus type 1.
od: Nordström, E, i dr.
Izdano: (2005)

Induction of human immunodeficiency virus (HIV-1) envelope specific cell-mediated immunity by a non-homologous synthetic peptide.
od: Ammar Achour, i dr.
Izdano: (2007-11-01)

A DNA/MVA-based candidate human immunodeficiency virus vaccine for Kenya induces multi-specific T cell responses in rhesus macaques.
od: Wee, E, i dr.
Izdano: (2002)

Relevance of the antibody response against human immunodeficiency virus type 1 envelope to vaccine design.
od: Parren, P, i dr.
Izdano: (1997)

MODELING THE CYTOTOXIC IMMUNE RESPONSE EFFECTS ON HUMAN IMMUNODEFICIENCY VIRUS
od: Jeimy Lorena Pérez Ibarra, i dr.
Izdano: (2014-12-01)

Specific proliferative T cell responses and antibodies elicited by vaccination with simian immunodeficiency virus Nef do not confer protection against virus challenge.
od: Wade-Evans, A, i dr.
Izdano: (2001)

Evaluation of response to hepatitis B virus vaccine in adults with human immunodeficiency virus
od: Arlete F. Rech-Medeiros, i dr.
Izdano: (2019-09-01)

Induction of simian immunodeficiency virus (SIV)-specific CTL in rhesus macaques by vaccination with modified vaccinia virus Ankara expressing SIV transgenes: influence of pre-existing anti-vector immunity.
od: Sharpe, S, i dr.
Izdano: (2001)

Emerging Targets for Developing T Cell-Mediated Vaccines for Human Immunodeficiency Virus (HIV)-1
od: Danushka K. Wijesundara, i dr.
Izdano: (2017-10-01)

Erratum to "Relevance of the antibody response against human immunodeficiency virus type 1 envelope to vaccine design".
od: Parren, P, i dr.
Izdano: (1997)

Nucleocapsid-like particles, an alternative and safe vaccine strategy against Dengue virus based on the induction of cell-mediated alone adaptive immune responses
od: Lázaro Gil, i dr.
Izdano: (2018-03-01)

The immune response to human immunodeficiency virus type 1 (HIV-1)
od: Turnbull, E, i dr.
Izdano: (2005)

Immunity to Human Immunodeficiency Virus (HIV) Infection
od: Carlo Torti, i dr.
Izdano: (2012-01-01)

Human immunodeficiency virus type 1-specific immune responses in primates upon sequential immunization with adenoviral vaccine carriers of human and simian serotypes.
od: Reyes-Sandoval, A, i dr.
Izdano: (2004)

Pentavalent HIV-1 vaccine protects against simian-human immunodeficiency virus challenge
od: Todd Bradley, i dr.
Izdano: (2017-06-01)

Antiretroviral agents against human immunodeficiency virus
od: Ingrid Barcelos de Oliveira, i dr.
Izdano: (2022-01-01)

Development of vaccines against gonorrhoea, syphilis, chlamydia, herpes simplex virus, human immunodeficiency virus and Zika virus
od: McIntosh D.
Izdano: (2019-12-01)

Human immunodeficiency virus type 1-hepatitis C virus coinfection: intraindividual comparison of cellular immune responses against two persistent viruses.
od: Lauer, G, i dr.
Izdano: (2002)

Erratum: Clinical experience with plasmid DNA- and modified vaccinia virus Ankara-vectored human immunodeficiency virus type 1 clade A vaccine focusing on T-cell induction (Journal of General Virology (2007) vol. 88 ( 1) (1-12))
od: Hanke, T, i dr.
Izdano: (2008)

Replication-deficient recombinant adenoviruses expressing the human immunodeficiency virus Env antigen can induce both humoral and CTL immune responses in mice.
od: Bruce, C, i dr.
Izdano: (1999)

Escape of human immunodeficiency virus from immune control.
od: McMichael, A, i dr.
Izdano: (1997)

Immunization of children at risk of infection with human immunodeficiency virus
od: Moss William J., i dr.
Izdano: (2003-01-01)

Genetic diversity of human immunodeficiency viruses and antiretroviral therapy
od: M R Bobkova
Izdano: (2016-11-01)

The Effect of Human Immunodeficiency Virus and Cytomegalovirus Infection on Infant Responses to Vaccines: A Review
od: Olivia Falconer, i dr.
Izdano: (2018-03-01)

Antibody Responses to Trivalent Influenza Vaccine in Iranian Adults Infected with Human Immunodeficiency Virus
od: Mehrnaz Rasoolinejad, i dr.
Izdano: (2013-03-01)

Antibody Responses to Trivalent Influenza Vaccine in Iranian Adults Infected with Human Immunodeficiency Virus
od: Mehrnaz Rasoolinejad, i dr.
Izdano: (2013-03-01)

Induction of Autophagy to Achieve a Human Immunodeficiency Virus Type 1 Cure
od: Grant R. Campbell, i dr.
Izdano: (2021-07-01)

Influence of immune activation and inflammatory response on cardiovascular risk associated with the human immunodeficiency virus
od: Beltrán LM, i dr.
Izdano: (2015-01-01)

Immunogenicity and Efficacy of Vaccination in People Living with Human Immunodeficiency Virus
od: Eeva Tortellini, i dr.
Izdano: (2023-08-01)

Impact of age and pre-existing immunity on the induction of human antibody responses against influenza B viruses
od: Michael A. Carlock, i dr.
Izdano: (2019-09-01)

Induction of Neutralizing Responses against Autologous Virus in Maternal HIV Vaccine Trials
od: Eliza D. Hompe, i dr.
Izdano: (2020-06-01)

A human immunodeficiency virus 1 (HIV-1) clade A vaccine in clinical trials: stimulation of HIV-specific T-cell responses by DNA and recombinant modified vaccinia virus Ankara (MVA) vaccines in humans.
od: Mwau, M, i dr.
Izdano: (2004)

Vaccine platform for prevention of tuberculosis and mother-to-child transmission of human immunodeficiency virus type 1 through breastfeeding.
od: Im, E, i dr.
Izdano: (2007)

Human Immunodeficiency Virus
od: Gupta, R, i dr.
Izdano: (2009)

Relevance of the antibody response against human immunodeficiency virus type 1 envelope to vaccine design (vol 57, pg 105, 1997)
od: Parren, P, i dr.
Izdano: (1997)